Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia

[11] Lazarus HM(2011)Polypharmacy in elderly patients with cancer: clinical implications and management Lancet Oncol 12 1249-1190

[12] Litzow MR(2014)The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML) Leuk Res 38 1184-83

[13] Luger S(2001)Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience Am J Hematol 67 73-467

[14] Fielding AK(2016)Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease Cancer 123 459-214

[15] Rowe JM(2010)A population-based cytogenetic study of adults with acute lymphoblastic leukemia Blood 115 206-3197

[16] Buck G(2007)Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial Blood 109 3189-626

[17] Foroni L(2017)The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era—a surveillance, epidemiology, and end results database analysis Br J Haematol 179 618-ee90

[18] Gerrard G(2017)BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors Haematologica 102 e187-3724

[19] Litzow MR(2017)TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens Cancer 123 3717-711

[20] Lazarus H(2017)The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases Leukemia 31 705-3817

[11] Lazarus HM(2011)Polypharmacy in elderly patients with cancer: clinical implications and management Lancet Oncol 12 1249-1190

[12] Litzow MR(2014)The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML) Leuk Res 38 1184-83

[13] Luger S(2001)Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience Am J Hematol 67 73-467

[14] Fielding AK(2016)Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease Cancer 123 459-214

[15] Rowe JM(2010)A population-based cytogenetic study of adults with acute lymphoblastic leukemia Blood 115 206-3197

[16] Buck G(2007)Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial Blood 109 3189-626

[17] Foroni L(2017)The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era—a surveillance, epidemiology, and end results database analysis Br J Haematol 179 618-ee90

[18] Gerrard G(2017)BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors Haematologica 102 e187-3724

[19] Litzow MR(2017)TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens Cancer 123 3717-711

[20] Lazarus H(2017)The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases Leukemia 31 705-3817